Lantheus Holdings Aktie

Lantheus Holdings für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A117UE / ISIN: US5165441032

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
06.08.2025 21:11:35

Lantheus (LNTH) Q2 Revenue Falls 4%

Lantheus (NASDAQ:LNTH), a developer of diagnostic and therapeutic radiopharmaceuticals, reported results on August 6, 2025, for Q2 FY2025. In its latest release, the company missed both GAAP revenue and non-GAAP earnings estimates.—reporting GAAP revenue of $378.0 million versus analyst expectations of $387.94 million, and adjusted earnings per share (EPS) of $1.57 versus the consensus estimate of $1.68. Both figures also declined compared to the prior year, with GAAP revenue down 4.1% and adjusted fully diluted earnings per share (non-GAAP) down 12.8%. The company also cut its full-year FY2025 financial outlook, lowering revenue guidance to $1.475 billion–$1.51 billion and adjusted fully diluted EPS guidance to $5.50–$5.70, reflecting continued pressure on its key PYLARIFY prostate cancer diagnostic business and a reset of growth assumptions. Overall, the quarter showed softer operational performance, but saw progress in diversification and investments to support future growth. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Lantheus focuses on imaging agents and therapeutics for oncology, neurology, and cardiology applications. Its core business is in radiopharmaceuticals, which are drugs containing radioactive isotopes for diagnosing and treating disease. Key marketed products include PYLARIFY, a positron emission tomography (PET) imaging agent used to detect prostate cancer, and DEFINITY, an ultrasound enhancing agent for cardiac imaging.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Lantheus Holdings Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Lantheus Holdings Inc 44,78 -0,44% Lantheus Holdings Inc
Q2 Holdings Inc 56,50 0,00% Q2 Holdings Inc